Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric heart failure trial of finerenone versus placebo on top of standard care
MOH_2025-12-15_015545Phase 3Recruiting
- Sponsor
- Bayer
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) and left ventricular systolic dysfunction (LVSD) comparing Finerenone + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Change in NT-proBNP and Safety and tolerability. Started Dec 2025; status: recruiting.
02
Drugs
finerenone
03
Conditions
heart failure (HF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on MOH_2025-12-15_015545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-15_015545.